Truist Financial Corp increased its position in shares of Sportradar Group AG (NASDAQ:SRAD – Free Report) by 4.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,829 shares of the company’s stock after purchasing an additional 973 shares during the quarter. Truist Financial Corp’s holdings in Sportradar Group were worth $613,000 as of its most recent filing with the SEC.
Several other large investors have also recently made changes to their positions in SRAD. Driehaus Capital Management LLC purchased a new stake in shares of Sportradar Group during the first quarter worth approximately $48,596,000. T. Rowe Price Investment Management Inc. acquired a new position in Sportradar Group during the first quarter worth $20,657,000. AM Investment Strategies LLC boosted its stake in Sportradar Group by 886.7% during the second quarter. AM Investment Strategies LLC now owns 460,690 shares of the company’s stock worth $12,936,000 after buying an additional 414,000 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Sportradar Group by 175.4% during the first quarter. Goldman Sachs Group Inc. now owns 610,384 shares of the company’s stock worth $13,197,000 after buying an additional 388,769 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Sportradar Group by 34.9% during the first quarter. Acadian Asset Management LLC now owns 1,461,619 shares of the company’s stock worth $31,574,000 after buying an additional 378,163 shares during the last quarter.
Sportradar Group Price Performance
SRAD opened at $27.51 on Thursday. The stock’s 50-day moving average price is $29.24 and its 200 day moving average price is $26.56. Sportradar Group AG has a 12-month low of $12.20 and a 12-month high of $32.22. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.04. The firm has a market cap of $8.24 billion, a price-to-earnings ratio of 76.42 and a beta of 2.02.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on SRAD. The Goldman Sachs Group began coverage on Sportradar Group in a research note on Monday, July 21st. They set a “neutral” rating and a $31.00 price objective on the stock. Morgan Stanley boosted their price objective on Sportradar Group from $25.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Jefferies Financial Group boosted their price objective on Sportradar Group from $27.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, July 3rd. Needham & Company LLC boosted their price objective on Sportradar Group from $28.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Finally, Truist Financial boosted their price objective on Sportradar Group from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, July 16th. Fourteen equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Sportradar Group currently has an average rating of “Moderate Buy” and a consensus target price of $31.88.
Check Out Our Latest Stock Analysis on Sportradar Group
Sportradar Group Company Profile
Sportradar Group AG, together with its subsidiaries, provides sports data services for the sports betting and media industries in the United Kingdom, the United States, Malta, Switzerland, and internationally. Its sports data services to the bookmaking under the Betradar brand name, and to the international media industry under the Sportradar Media Services brand name.
Featured Stories
- Five stocks we like better than Sportradar Group
- How to Read Stock Charts for Beginners
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Investing In Preferred Stock vs. Common Stock
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Sportradar Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sportradar Group and related companies with MarketBeat.com's FREE daily email newsletter.